Glycosaminoglycans (GAGs) are necessary for biological functions, including anti-coagulation, wound healing, and the regulation of the proliferation of bacteria, virus and tumor cells. GAG-based therapeutics are typically administrated via a parenteral route, which is ineffective for the treatment of diseases that requires a local administration. In this work, selected GAG-based biotherapeutics, including one proteoglycan, were successfully encapsulated with high efficiency in three different pH-responsive metal-azolate frameworks (ZIF-8, ZIF-90, and MAF-7). The resultant GAG@MOF biocomposites present significant differences in terms of crystallinity, particle size, and spatial distribution of the cargo, which influences the drug-release kinetics upon applying an acidic stimulus. The present work provides a straightforward approach to modulate the release properties of the biocomposite by altering the MOF shell and offers a targeted strategy for the more effective delivery of GAGs.
Introduction
Metal-organic frameworks (MOFs) are a class of extended materials composed of metal nodes connected via multidentate organic linkers. [1, 2] The chemical mutability of these building blocks permits tailoring the properties of MOFs for applications ranging from gas storage to chemical sensing and catalysis. [3, 4] More recently, MOFs have been studied for drug delivery because of their high encapsulation efficiency, tunable release profile, high selectivity toward specific cells and tissues, and low cytotoxicity. [5] MOFs can be loaded with different therapeutics, including biomacromolecules and assembly of thereof (proteins, DNA, viruses and cells). [6] [7] [8] In these cases, the MOF coating acts as a protective shell that can be dissolved under controlled conditions to release the bioentities. [7, [9] [10] [11] [12] The incorporation of large biomolecules within Zn-based zeolitic imidazolate frameworks (ZIFs), [13] [14] [15] [16] including ZIF-8 and related topologies, ZIF-90 and MAF-7 [17] [18] [19] [20] is commonly achieved via an approach termed biomimetic mineralization. [6] [7] [8] The widespread interest in ZIFs for the encapsulation of biomacromolecules is due to their compatibility with aqueous synthetic conditions, [6] their hydrolytic stability, [21] and their controlled release properties (e.g. via acidic pH or addition of chelating agents). [22] These properties have been exploited for the design of stimulus-responsive drug delivery systems. [23] [24] [25] [26] Despite the versatility of the encapsulation protocol, we recently demonstrated that not all the biomacromolecules are prone to induce the spontaneous crystallization of ZIFs. [27] For example, negatively charged molecules trigger the growth of biocomposites, while their positively charged counterparts prevent their spontaneous formation. [27] These results underscore the importance of electrostatic interactions between target biomolecules and Zn 2+ ions, as an increased local concentrations of Zn 2+ at the surface of the biomolecule triggers the self-assembly of the framework. Here, we hypothesize that this approach can be applied to the design of ZIF-based drug carriers for highly-negative charged biotherapeutics such as glycosaminoglycans (GAGs). [28] GAGs are unbranched high-molecular weight polysaccharides formed from disaccharide units that consist of an amino sugar (D-glucosamine or D-galactosamine), and uronic acid (D-glucuronic acid or L-iduronic acid). The multiple carboxylate and sulfate moieties attached to the carbohydrate backbone impart the negative charge to GAGs. [28] The most common GAGs are heparin (HP), chondroitin sulfate (CS), dermatan sulfate (DS), and hyaluronic acid (HA). [28, 29] They naturally occur either covalently linked to proteins, forming proteoglycans, or free within the extracellular matrix. [28, 29] In living organisms, GAGs are involved in a variety of biological roles, including anti-coagulation, wound healing, lubrication of synovial joints, cell signalling, angiogenesis, and axonal growth. [28] [29] [30] [31] GAGs can be used as therapeutics to prevent the proliferation of bacteria (e.g. Mycobacterium tuberculosis), and viruses (e.g. Herpes simplex). [28] [29] [30] [31] [32] Recently, the relevance of GAGs to vaccines, protein and antibody modifications, and polyvalent glycan therapeutics has been highlighted by Paderi and co-workers. [33] Furthermore, due to the important role of proteoglycans in tumour progression and metastasis, GAGs have been applied to the design of novel anticancer therapeutics. [28, 29, 31] Accordingly, GAGs can be considered the most exploited carbohydrate in the pharmaceutical market. [29] GAGs-based therapeutics are typically administered via the parenteral route as their bioavailability is compromised in the gastrointestinal tract . [28, 34, 35] Dosing of GAGs, via the parenteral route requires careful monitoring, as an excess of the drug can lead to bleeding as result of their anticoagulant properties. [34, 35] This method of administration is not compatible with all disease treatments such as wound healing and anti-inflammatory applications that require efficient local administration. As a consequence, novel carriers with customizable delivery properties for the administration of GAGs are desirable.
This study presents a straightforward approach to circumvent those problems through the modulation of the drug release kinetics of the resultant biocomposites by tuning the physicochemical properties of the MOF shell. Three different Zn-based metal-azolate frameworks (ZIF-8, ZIF-90, and MAF-7), of markedly different hydro-phobicity/-philicity, [36, 37] were employed to encapsulate a selected set of GAGs-based therapeutics (HA, HP, CS, DS, GM-1111, and HepSYL, where the last two are synthetic drugs in preclinical development). [33, 38, 39] The encapsulation efficiencies (EE%) and therapeutic release profiles of each biocomposite were assessed as these are crucial information for the development of drug delivery systems. [25] For the first time we demonstrated that the release of pharmacologically relevant carbohydrate-based therapeutics can be performed using azolate-based MOF particles and the drug release properties can be precisely tuned by the judicious choice of the MOF material.
Results and Discussion
ZIF-8-based biocomposites have been intensively studied for their drug release properties, however limited or no attention has been paid to ZIF-90 and MAF-7 as drug carriers, respectively. [25, 40, 41] Although, ZIF-8, ZIF-90 and MAF-7 are isostructural, they are composed of different organic linkers and possess distinct chemical properties. [17, 36, 37] For example, ZIF-8 (2methylimidazole; HmIM) is more hydrophobic than ZIF-90 (2-imidazole carboxaldehyde; HICA) and MAF-7 (3-methyl-1,2,4triazole; Hmtz). [36, 37] We posit that the different properties of these ZIFs could influence their performance as drug delivery carriers.
To verify this hypothesis, we encapsulated different GAGs-based therapeutics (HA, HP, CS, DS, GM-1111, and HepSYL) within ZIF-8, ZIF-90, and MAF-7 (Scheme 1) and examined the performance characteristics of the different GAG@ZIF biocomposites as carriers for pH-responsive delivery. For each system, we determined the encapsulation efficiency (EE%) and the drug release profiles. [42] However, we first focused our attention on finding the synthetic conditions to optimize the drug loading and release properties of the biocomposites derived from the three different MOF systems (ZIF-8, ZIF-90, and MAF-7).
Given that there are no previous studies describing the encapsulation of carbohydrates in ZIF-90 and MAF-7, we used carboxymethyl-dextran tagged with fluorescein isothiocyanate (FITC-CMD), as a model therapeutic to determine if charbohydrate-based biocomposites of these ZIFs could be obtained. FITC-CMD was selected as it is an inexpensive carbohydrate that closely mimics GAGs, and the fluorescein tag permits quantification of the amount of encapsulated CMdextran (Figure S1-S3). [22] The synthesis of FITC-CMD@ZIF-8 FITC-CMD@ZIF-90 and FITC-CMD@MAF-7 was performed by varying the concentration of the biomolecule ([FITC-CMD] = 0 (1), 0.18 (2), 0.36 (3), 0.72 (4), 1.44 (5) mg mL -1 ) and the metal to ligand ratio (Zn 2+ :L = 1:4 (A), 1:3.47 (B) and 1:2.52 (C)) (Table S1 and S2). The data shows that for FITC-CMD@ZIF-8 biocomposites the optimal encapsulation efficiencies (> 90%) were reached using 0.36 and 0.72 mg mL -1 of FITC-CMD and metal to ligand ratios of 1:4 (A) and 1:3.47 (B) ( Figure S1 ). In the case of FITC-CMD@ZIF-90 biocomposites the higher EE% values (> 90%) were observed for samples obtained from the lowest concentration of FITC-CMD (0.18 mg mL -1 ), for both 1:3.47 (B) and 1:2.52 (C) Zn 2+ :HICA ratios ( Figure S2 ). Conversely, FITC-CMD@MAF-7 biocomposites present exceptional polysaccharide payloads regardless of the initial concentration of FITC-CMD, when using 1:3.47 (B) Zn 2+ :Hmtz ratio ( Figure  S3 ). The drug release kinetics of the FITC-CMD@ZIF-8, FITC-CMD@ZIF-90 and FITC-CMD@MAF-7 biocomposites were obtained upon applying an external acidic stimulus ( Figure S4-S6 ). The release profiles show that the higher the concentration of the FITC-CMD the faster the delivery of the cargo. However, for biocomposites obtained from 0.72 mg mL -1 and 1.44 mg mL -1 of FITC-CMD we measured leaching of the model drug during the incubation of the samples in DI water for 24 h at room temperature. Thus, the maximum concentration of FITC-CMD that afforded controlled stimulus-response drug release was 0.36 mg mL -1 .
In summary, employing FITC-CMD, as model drug, we found that a metal to ligand ratio of 1.3.47 and a carbohydrate concentration of 0.36 mg mL -1 yielded acceptable EE% and facilitates the release of the model therapeutic on demand. Accordingly, these synthetic conditions were employed for the encapsulation of selected GAG-based therapeutics (i.e. HA, HP, CS, DS) (Scheme 1). The biocomposites derived from ZIF-8 and ZIF-90 were isolated as crystalline precipitates (HA@ZIFn, HP@ZIF-n, CS@ZIF-n, and DS@ZIF-n, where n = 8 and 90; respectively). However, the MAF-7-based biocomposites formed either viscous solutions with a gel-like consistency (HA@MAF-7, HP@MAF-7, CS@MAF-7, and DS@MAF-7) or nonflowing gels (HA@MAF-7).The formation of Metal-organic gels (MOGs) has been previously explained as a result of the rapid formation of MOF nanoparticles, which aggregate through weak van der Waals interactions, H-bonding or π-π stacking. [43] [44] [45] After the 24 h, samples were washed with water and ethanol (see Supporting Information) and the air-dried solids were analysed by powder X-ray diffraction (PXRD) (Figure 1 ).
The diffraction patterns show that the control sample (ZIF-8 precursors without biotherapeutic) possess predominantly a diamondoid topology (dia), while the GAG@ZIF-8 biocomposites are of sodalite (sod) topology ( Figure 1a ). These data indicate that the GAGs enhance the rate of formation of the ZIF yielding the less thermodynamically stable sod topology. [46] The PXRD pattern of ZIF-90, prepared in the absence of GAGs, is consistent with the dia polymorph. However, in presence of the biomolecule the resultant GAG@ZIF-90 biocomposites show a mixture of kinetic sod-ZIF-90 and the thermodynamic polymorph dia-ZIF-90 (Figure 1b) .
Finally, the diffraction pattern of MAF-7 reveals the formation of a material of poor crystallinity accompanied by the presence of an amorphous phase (Figure 1c ). The diffraction patterns obtained from the GAG@MAF-7 biocomposites indicate that HA@MAF-7 and HP@MAF-7 are predominantly amorphous, whereas DS@MAF-7 shows a mixture of crystalline and amorphous phase. The sample CS@MAF-7 gives rise to a PXRD pattern with broad diffraction peaks that can be attributed to the presence of nanoparticles with domain sizes between (33.2(17) to 927(49) Å) as determined by the Scherrer equation (Figure 1c ). The crystal size and the morphology of the control samples of MOFs and their corresponding GAG@MOF biocomposites were assessed by SEM (Figure 1 ). The micrographs obtained from the control sample of ZIF-8 show the formation of plate-like crystals, which is the typical morphology observed in dia-ZIF-8 topology. [18, 20, 46] For GAG@ZIF-8 (Figures 1d) , the characteristic rhombic dodecahedron morphology of sod-ZIF-8 topology is present. [18, 20, 46] [18] The crystalline powder obtained from HP@ZIF-90, CS@ZIF-90, and DS@ZIF-90 possesses particle sizes ranging from ca. 5 µm to ca. 7 µm; whereas HA@ZIF-90 presents a wider particle size distribution ranging from ca. 500 nm to ca. 4 µm ( Figures S9 and S10 ). Furthermore, mesopores are observed on the surface of some of the GAG@ZIF-90 crystals. Although this is more evident for HP@ZIF-90, this can be seen for CS@ZIF-90, and DS@ZIF-90 (Figures 1e and S10) . Similar textural features have been previously found in other MOFs, prepared in the presence of longchain carboxylic acids. [47, 48] Due to the fine particle sizes of the MAF-7 materials, they were studied using TEM (Figure 1f ). The images show that the solid materials obtained for pure MAF-7 and GAGs@MAF-7 consist of aggregated nanoparticles with an average size below 100 nm (Figures S11 and S12). To ascertain the encapsulation of GAGs within the ZIF matrices, the samples were washed with water (2 mL, 3x) and ethanol (2mL, 3x) to ensure the complete removal of GAGs loosely attached to the particle surface. [22] Then the collected solids were analyzed by Fourier transform infrared spectroscopy (FTIR) (Figures S13-S17). IR spectra obtained from GAGs@ZIFs biocomposites show the vibration bands typically attributed to the ZIF framework including the Zn-N stretching mode (421 cm −1 ) and characteristic vibrational modes of the azolate ligands (1584 cm −1 (νC=N), 1500-1350 cm −1 (νring) and 800-650cm −1 (δring)) ( Figure S13 ). For each GAG used, additional bands originating from the specific pendant groups were observed. [49] For example, the vibrational bands attributed to the carboxylic groups are found around 1610-1620 cm -1 νas(COO -) and 1410-1420 cm -1 νs(COO -). Furthermore, all of the spectra also display a broad band around 2850-3600 cm -1 , that results from the stretching modes of the OH group, as well as the band attributed to C-O stretching vibration around 1020-1040 cm -1 . [49] Finally, those biocomposites obtained from sulfated biomacromolecules (HP, CS, and DS) present additional weak vibrational bands at 1220-1240 cm -1 νas(S=O), and 1000-822 cm -1 (OSO3 -) ( Figures S14-S17 ). [49] The encapsulation efficiency (EE%) of each GAG@MOF biocomposite was assessed using UV-vis spectroscopy and the carbazole assay; which is a direct method to quantify glycosaminoglycans by colorimetry (lmax 520 nm) (see Supporting information for details). [50, 51] The GAG@MOF samples, were soaked, separately, in citrate buffer (2 mL, 80 mM, pH = 6) to dissolve the MOFs. Once a clear solution was obtained, a Sephadex column was used to separate the GAGs from the MOF precursors. For these clinical biotherapeutics, the MAF-7-based biocomposites present the highest EE% reaching values above 80% (Figure 2a ) and the GAG@ZIF-90 biocomposites display the lowest EE% (ca. 50%) (Figure 2a ). In the case of ZIF-8, the biocomposites obtained from HP and CS present exceptional EE% (ca. 100%), however, those derived from HA, and DS show an EE% of ca. 60% (Figure 2a ). The drug-release profile studies were determined by quantifying the amount of GAG delivered in citrate buffer (80 mM, pH = 6) as a function of time (see Supporting information). The citrate buffer was employed with the aim of emulating the interstitial tissue pH found in inflammatory diseases and in cancer cells. [52, 53] All the release profiles present an initial rapid release of the biotherapeutic, followed by a slower sustained delivery. Nevertheless, each MOF-system shows unique release behaviour (Figures 2b-2e ). For instance, the release profiles of GAG@MAF-7 biocomposites exhibit a large initial burst release, where ca. 50% of the cargo was liberated within the first minute, reaching the complete delivery within 30 min ( Figure S18) .
The observed burst effect for MAF-7-based biocomposites, irrespective of the GAG used, can be explained by the rapid degradation of the small nanoparticles. In the case of GAG@ZIF-8 biocomposites, the initial release rate in the burst stage varies: CS@ZIF-8 and DS@ZIF-8 present the fastest initial drug release (ca. 50% within the first minute), reaching the complete delivery of the cargo after 1h (Figures 2d and 2e ). HP@ZIF-8 and HA@ZIF-8 show a 50% release of the cargo within 5 min, and 100% release after 40 min (Figures 2b and 2c) . GAG@ZIF-90 composites display a sustained longer-term release profile. The initial burst stage is observed in 10 to 15 min, and ca. 50% of the loaded drug was released, followed by a gradual delivery of the cargo where the complete release ranges from 50 min (HP@ZIF-90) to 1.5 h (HA@ZIF-90, CS@ZIF-90 and DS@ZIF-90) (Figures 2 and S18 ). In summary, by using different azolate-based MOFs we proved that we can design systems for the customized release of carbohydrate based therapeutics from fast delivery, useful in case of infections, [54] to longer delivery desired in case of anticoagulant administration. [55] To this point we have established that carbohydrate-based drugs can be encapsulated with high efficiency and their release controlled by the judicious selection of the MOF matrix (ZIF-8, ZIF-90 and MAF-7), thus we expanded our study to the assessment of ZIFs for the delivery of carbohydrate-based drugs in late-stage clinical trials. Thus we employed two preclinical stage bio therapeutics; GM-1111 and HepSYL. [33, 38, 39] GM-1111 is an anti-inflammatory agent engineered to treat chronic rhinosinusitis, as it inhibits multiple inflammatory mediators and requires topical intranasal administration route [56] and HepSYL is a new synthetic proteoglycan designed for oncotherapy applications. As such, a parenteral administration route is needed. GM-1111 and HepSYL were encapsulated within ZIF-8, ZIF-90 and MAF-7 following the synthetic protocol used for the GAGs based therapeutics (see Supporting Information). After washing and drying, the powders were examined with PXRD.
The diffraction patterns indicate that GM-1111@ZIF-8 and HepSYL@ZIF-8 are a mixture of different crystalline phases, sod, dia, and ZIF-C, [20, 57] with sod as the predominant phase ( Figure 3a) . By contrast, the diffraction pattern of GM-1111@ZIF-90 and HepSYL@ZIF-90 show that the samples are pure sod phase (Figure 3a) . GM-1111@MAF-7 and HepSYL@MAF-7 yield amorphous materials, (Figure 3a) . SEM analysis reveals that the crystalline particles of GM-1111@ZIF-8 and HepSYL@ZIF-8 are of rhombic dodecahedron morphology (Figure 3b ). For GM-1111@ZIF-8 we observed inhomogeneous particles with average size of ca. 500 nm; while for HepSYL@ZIF-8 the particle are homogeneous with size is below 200 nm. Likewise, the particle morphology observed in GM-1111@ZIF-90 and HepSYL@ZIF-90 samples corresponds to rhombic dodecahedron, with particle sizes of ca. 8 µm and ca. 2 µm, respectively (Figure 3b ). Due to the small particle size, GM-1111@MAF-7 and HepSYL@MAF-7 samples were analysed by TEM (Figure 3b ). The images reveal the formation of aggregates comprised of nanoparticles with an average size below 50 nm. Finally, confocal laser microscopy (CLSM, see SI) was employed to ascertain the location of HepSYL within the ZIF particles (Figures 3c and S19) . The CLSM images show that the proteoglycan is homogeneously distributed within ZIF-8 and MAF-7. However, in the case of HepSYL@ZIF-90, the proteoglycan is predominantly localized on the subsurface of crystalline particles. The encapsulation efficiency and the drug-release kinetics of GM-1111@MOF and HepSYL@MOF were assessed using UVvis spectroscopy (Figure 4a ). Following the protocol previously described for GAG-based biocomposites, the amount of GM-1111 encapsulated within the MOF shell was determined using the carbazole assay (lmax = 520 nm). [50, 51] In the case of HepSYL@ZIFs biocomposites, the EE% was determined by monitoring the absorbance of the colorant used to label the protein (CF633, l = 633 nm) ( Figure S20 ). The data collected reveals that the best performance, in terms of EE%, was found when using MAF-7, followed by ZIF-90 and then ZIF-8 (Figure 4a ). The EE% is also influenced by the biomacromolecule. GM-1111, that is more structurally similar to GAGs, shows a higher EE% than HepSYL, which contains positively charged peptides.
The drug release profiles of GM-1111@ZIFs reveal that GM-1111@MAF-7 and GM-1111@ZIF-8 present a rapid burst release upon applying an external acidic stimulus (pH = 6), and complete release was achieved within the first 20 min ( Figure  4b ). The release profile of GM-1111@ZIF-90 presents a long-term controlled drug delivery, with complete release observed after 2.5 h (Figure 4b) .
Finally, the HepSYL@ZIF release profiles reveal that the fastest drug delivery is determined for HepSYL@MAF-7, while HepSYL@ZIF-8 and HepSYL@ZIF-90 exhibit a longer-term drug release (Figure 4c ). The complete release of the anticarcinogenic therapeutic was observed after 2 h and 2.5 h; respectively (Figure 4c ).
Conclusion
In summary, three chemically different azolate-based frameworks (ZIF-8, ZIF-90, and MAF-7), were used to design pHresponsive carriers for the encapsulation and release of GAG-based biotherapeutics including heparin (HP), chondroitin sulfate (CS), dermatan sulfate (DS), and hyaluronic acid (HA). Based on the selection of the ZIF matrices, the encapsulation efficiency varied from 50 to 100% range and the release of the clinical therapeutics could be precisely tailored. For instance, where a fast release is desired (e.g. in the treatment of infection-related diseases as the case of osteomyelitis, [58] in wound treatment, [54] or in pulsatile delivery processes), [59] the choice could lead towards the use of GAG@ZIF-8, and GAG@MAF-7 biocomposites. However, if a controlled and sustained release of biomolecule is required to reduce the systemic side effects associated with high drug concentrations or to avoid the frequency of drug administration, [54] GAG@ZIF-90 biocomposites represent a desirable alternative. Finally, the azolate-based MOF carriers were employed for the encapsulation and release of pre-clinical therapeutics used as anti-inflammatory and anticarcinogenic agents.
Similar to the GAG-based biocomposites the EE% and release profiles could be tailored by the judicious selection of the MOF matrix. We anticipate that our findings will facilitate progress in the burgeoning area of MOF-based drug delivery. 
Experimental Section
Experimental details can be found in the Supporting Information.
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